BUSA - ETF AI Analysis
Top Page
Brandes U.S. Value ETF (BUSA)
BUSA, the Brandes U.S. Value ETF, earns a solid overall rating thanks to several high-quality holdings with strong financial performance and growth prospects. Standout positions like Alphabet (GOOG), Merck (MRK), and Intercontinental Exchange (ICE) support the fund’s quality through robust profitability, attractive valuations, and positive earnings outlooks, while names such as Chevron (CVX) and Pfizer (PFE) introduce some short-term challenges around revenue growth and sector-specific risks. The main risk factor is the fund’s exposure to a mix of companies where some show signs of overvaluation or bearish technical trends, which could add volatility even though the overall long-term outlook is positive.
BUSA vs. SPDR S&P 500 ETF (SPY)
- AUM
- 422.12M
- Region
- North America
- Expense Ratio
- 0.60%
- Beta
- 0.66
- Issuer
- Brandes
- Inception Date
- Oct 03, 2023
- Dividend Yield
- 1.46%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
BUSA Summary
Brandes U.S. Value ETF (BUSA) is a fund that invests mainly in U.S. companies that its managers believe are undervalued and out of favor, but still have solid business foundations. It doesn’t track a specific index, but follows a value investing theme across many sectors like health care, financials, and industrials. Well-known holdings include Bank of America, Chevron, Pfizer, and Merck. Someone might invest in BUSA to seek long-term growth while spreading their money across many different industries. A key risk is that value stocks can stay unpopular for long periods, and the ETF’s price can go up and down with the overall stock market.
How much will it cost me?
This ETF has an expense ratio of 0.60%, which means you’ll pay about $6 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because BUSA is actively managed, with professionals selecting value stocks rather than simply tracking a market index.
What would affect this ETF?
Because BUSA focuses on undervalued U.S. stocks, it could benefit if investors shift back toward value investing, the U.S. economy stays healthy, and sectors like health care and financials—where this ETF is heavily invested—see steady earnings and supportive regulations. On the other hand, rising interest rates, pressure on banks, weaker demand for medical and pharmaceutical products, or broad U.S. market downturns could hurt the fund’s holdings and weigh on future returns.
BUSA Top 10 Holdings
BUSA leans heavily into U.S. health care and financials, and its recent story is being written mostly by drugmakers and medical suppliers. Merck and Pfizer have been rising, giving the fund a solid health care backbone, while Becton Dickinson adds a steadier, more defensive note. On the industrial and energy side, Textron and Chevron are also helping, with both names trending positively. Offsetting some of that strength, Bank of America has been lagging, showing that not all value plays in the financial sector are paying off at the moment.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 BDX | Becton Dickinson | 3.31% | $13.78M | $56.98B | 21.07% | 67Neutral |
 TXT | Textron | 2.56% | $10.67M | $14.68B | 6.18% | 75Outperform |
 CI | Cigna | 2.67% | $11.10M | $80.70B | 16.14% | 72Outperform |
 MRK | Merck & Company | 2.51% | $10.47M | $370.96B | 74.12% | 80Outperform |
 EFX | Equifax | 2.44% | $10.14M | $22.49B | -6.51% | 71Outperform |
 ICLR | Icon | 2.27% | $9.46M | $15.22B | 23.18% | 68Neutral |
 SSNC | SS&C Technologies Holdings | 2.19% | $9.11M | $18.67B | -8.68% | 78Outperform |
 PFE | Pfizer | 2.23% | $9.27M | $175.50B | 21.41% | 74Outperform |
 ICE | Intercontinental Exchange | 2.26% | $9.42M | $97.76B | 19.01% | 80Outperform |
 CVX | Chevron | 2.02% | $8.42M | $423.29B | 39.48% | 71Outperform |
BUSA Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BUSA, the sentiment is Positive. The current price of 42.39 is above the 20-day moving average (MA) of 41.49, above the 50-day MA of 41.04, and above the 200-day MA of 39.41, indicating a bullish trend. The MACD of 0.54 indicates Negative momentum. The RSI at 60.21 is Neutral, neither overbought nor oversold. The STOCH value of 72.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BUSA.
BUSA Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| BUSA | $42.39 | $44.00(3.80% Upside) | $422.12M | 0.60% | 70Outperform |
 VFVA | $161.45 | $195.33(20.98% Upside) | $998.69M | 0.13% | 69Neutral |
 QVAL | $63.35 | $73.61(16.20% Upside) | $719.25M | 0.28% | 73Outperform |
 LSVD | $34.27 | $43.87(28.00% Upside) | $663.63M | 0.40% | 74Outperform |
 AIVL | $133.65 | $154.31(15.46% Upside) | $430.11M | 0.38% | 72Outperform |
 GVLU | $29.22 | $35.35(20.97% Upside) | $261.70M | 0.50% | 69Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BUSA | Brandes U.S. Value ETF | 42.39 | 8.21 | 24.01% | |
| VFVA | Vanguard U.S. Value Factor ETF | 161.45 | 38.28 | 31.08% | |
| QVAL | Alpha Architect U.S. Quantitative Value ETF | 63.35 | 17.62 | 38.53% | |
| LSVD | LSV Disciplined Value ETF | 34.27 | 5.73 | 20.07% | |
| AIVL | WisdomTree U.S. AI Enhanced Value Fund | 133.65 | 23.06 | 20.85% | |
| GVLU | Gotham 1000 Value ETF | 29.22 | 5.70 | 24.26% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.